Literature DB >> 19187954

Thromboelastography in patients with cerebral venous thrombosis.

Karen Koopman1, Maarten Uyttenboogaart, Herman G D Hendriks, Gert-Jan Luijckx, Ivo R Cramwinckel, Patrick C Vroomen, Jacques De Keyser, Jan van der Meer.   

Abstract

INTRODUCTION: Cerebral venous thrombosis (CVT) is a rare presentation of venous thrombosis and has been associated with many conditions. In about 20% no risk factor is identified. The aim of this study was to assess the clot formation by thromboelastography (TEG) in patients with a history of CVT compared with healthy controls.
MATERIALS AND METHODS: TEG analysis was performed on recalcified blood samples of 19 CVT patients from a single centre cohort and 1:1 sex/ age (+/-3 year) matched controls. Four TEG parameters were monitored: reaction time (r) to clot initiation, time to reach a 20 mm level of clot formation (K), slope angle alpha from r to K (alpha) and maximum vertical amplitude (MA). Patients were tested for thrombophilic defects, including deficiencies of antithrombin, protein C and protein S, factor V Leiden, prothrombin G20210A mutation, lupus anticoagulant, antiphospholipid antibodies, and high factor VIII levels.
RESULTS: Thrombophilia testing identified a prothrombotic abnormality in 11 patients (58%). Sixteen patients (84%) had one or more transient risk factor. There were no significant differences in TEG parameters between CVT patients and controls, neither between the subgroup of patients with a thrombophilic defect and controls. Seven of all patients (37%), including 5 patients with abnormal thrombophilia testing, and 5 controls (26%) had one or more TEG hypercoagulable parameters.
CONCLUSIONS: A persistent hypercoagulable state which could have predisposed to venous thrombosis in CVT patients and in the subgroup of patients with a thrombophilic defect could not be demonstrated by TEG.

Entities:  

Mesh:

Year:  2009        PMID: 19187954     DOI: 10.1016/j.thromres.2008.12.032

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  Association between thrombelastography system and thromboembolic and bleeding events in Chinese aged people.

Authors:  Jie Bai; Qi-Wen Zheng; Shu-Hong Fu; Xiao-Xia Li; Yu-Ru Li; Yu Zhou; Ji-Hong Yu; Mei-Liang Gong; Da-Fang Chen
Journal:  Int J Clin Exp Med       Date:  2013-04-12

Review 2.  [Diagnostic assessment of perioperative thromboembolism].

Authors:  Thomas Lang
Journal:  Wien Med Wochenschr       Date:  2009-10

3.  Statins improve the resolution of established murine venous thrombosis: reductions in thrombus burden and vein wall scarring.

Authors:  Chase W Kessinger; Jin Won Kim; Peter K Henke; Brian Thompson; Jason R McCarthy; Tetsuya Hara; Martin Sillesen; Ronan J P Margey; Peter Libby; Ralph Weissleder; Charles P Lin; Farouc A Jaffer
Journal:  PLoS One       Date:  2015-02-13       Impact factor: 3.240

4.  Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk.

Authors:  Elena N Lipets; Fazoil I Ataullakhanov
Journal:  Thromb J       Date:  2015-01-23

5.  Clinical analysis and misdiagnosis of cerebral venous thrombosis.

Authors:  Xiaotong Wang; Xuwen Sun; Hong Liu
Journal:  Exp Ther Med       Date:  2012-09-04       Impact factor: 2.447

Review 6.  Prevalence and Geographical Variation of Prothrombin G20210A Mutation in Patients with Cerebral Vein Thrombosis: A Systematic Review and Meta-Analysis.

Authors:  Joaquín V Gonzalez; Andrés G Barboza; Fernando J Vazquez; Esteban Gándara
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

7.  Factor V Leiden, factor V Cambridge, factor II GA20210, and methylenetetrahydrofolate reductase in cerebral venous and sinus thrombosis: A case-control study.

Authors:  Mohammad Saadatnia; Mansour Salehi; Ahmad Movahedian; Seyed Ziaeddin Samsam Shariat; Mehri Salari; Marzieh Tajmirriahi; Elham Asadimobarakeh; Rasoul Salehi; Gilda Amini; Homa Ebrahimi; Ehsan Kheradmand
Journal:  J Res Med Sci       Date:  2015-06       Impact factor: 1.852

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.